Education
About Us
Working with TipRanks
Follow Us
Viking Therapeutics (VKTX)
:VKTX
VKTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$18.92 - $81.73
Previous CloseN/A
Volume7.75M
Average Volume (3M)8.32M
Market Cap
$2.60B
Enterprise Value$2.16B
Total Cash (Recent Filing)$33.88M
Total Debt (Recent Filing)$878.00K
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Oct 22, 2025EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding112,444,960
10 Day Avg. Volume5,023,535
30 Day Avg. Volume8,319,307
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-24.88K
Enterprise Value/Ebitda-10.18
Forecast
1Y Price Target
$90.59Price Target Upside247.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Bulls Say, Bears Say
Bulls Say
EfficacyThe oral VK2735 demonstrated impressive weight loss of up to 12.2% compared to 1.3% for the placebo, showing competitive efficacy across multiple dose levels.
Market PositionThe totality of ‘2735’s data, including competitive efficacy from two large Phase 2 studies, suggests potential best-in-class performance.
Partnership OpportunitiesThe potential for a large pharma partner to address manufacturing capacity issues at higher doses is promising.
Bears Say
Competitive PositioningVKTX is trading down ~40%, and the selloff reflects near-term concerns around tolerability and discontinuation rates in higher doses and competitive positioning in the obesity class.
Market ReactionVKTX shares are under pressure following the data release and investor call, partly due to elevated expectations and concerns around the safety/tolerability profile of oral '2735.
Tolerability ConcernsTolerability was the clear miss with higher rates of adverse events than expected across the board.
Viking Therapeutics News
VKTX FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was $18.92 and its highest was $81.73 in the past 12 months.
What is Viking Therapeutics’s market cap?
Viking Therapeutics’s market cap is $2.60B.
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Oct 22, 2025 which is in 33 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Jul 24, 2025. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of -$0.446 by -$0.134.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -0.7.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 112,444,960 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$0.58 in its last earnings report, missing expectations of -$0.446. Following the earnings report the stock price went up 2.746%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Currently, no hedge funds are holding shares in VKTX
Viking Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$90.59 (247.89% Upside)
$90.59 (247.89% Upside)
Blogger Sentiment
Bullish
VKTX Sentiment 70%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 417.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $984.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.59%
12-Months-Change
Fundamentals
Return on Equity
-19.99%
Trailing 12-Months
Asset Growth
-12.57%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc. is a biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. The company is engaged in research and development activities aimed at advancing its portfolio of drug candidates, which target conditions such as liver disease, muscle wasting, and other metabolic disorders. Viking Therapeutics' strategy involves leveraging its expertise in drug discovery and development to address unmet medical needs with its innovative small molecule therapeutics.
VKTX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented both significant advancements in clinical trials and a strong financial position, but these were offset by increased expenses and net loss. The progress in clinical programs, particularly the VK2735 obesity program, is promising, but financial challenges remain.View all VKTX earnings summariesVKTX Stock 12 Month Forecast
Average Price Target
$90.59
▲(247.89% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Xenon
―
Scholar Rock Holding
―
Immunovant
―
NewAmsterdam Pharma Company
―
Ownership Overview
2.81% Insiders
22.70% Mutual Funds
11.18% Other Institutional Investors
51.15% Public Companies and Individual Investors